Company: REVB
Filing Date: 2025-04-04
Form Type: DRS
Source: 0001213900-25-029022
Chunk: 7

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-04-04
Form: DRS
Chunk 7
---
 at a specific ratio within a range of one -for -two(1 -for-2) to a maximum of a one -for -fifty(1 -for-50) split. Following the special meeting of stockholders and determination by the Board of Directors on the reverse split ratio, we filed a Certificate of Amendment effective on January 28, 2025, which effected a 1 -for-16reverse stock split of our outstanding shares of common stock as of 12:01 a.m. Eastern Standard Time on January 28, 2025. 2024 Reverse Stock Split On January 17, 2024, at a special meeting of stockholders, our stockholders approved a Certificate of Amendment to our Third Amended and Restated Certificate of Incorporation to effect a reverse stock split of our outstanding shares of common stock at a specific ratio within a range of one -for -two(1 -for-2) to a maximum of a one -for -fifty(1 -for-50) split. On January 22, 2024, we filed the Certificate of Amendment which effected a 1 -for-30reverse stock split of our outstanding shares of common stock as of 12:01 a.m. Eastern Standard Time on January 25, 2024. 2023 Change in Authorized Shares and Reverse Stock Split On January 30, 2023, at a special meeting of stockholders, our stockholders approved a Certificate of Amendment to our Third Amended and Restated Certificate of Incorporation to change the authorized common stock from 100,000,000 to 500,000,000shares and effect a reverse stock split of our outstanding shares of common stock at a specific ratio within a range of one -for -twenty(1 -for-20) to a maximum of a one -for -onehundred (1 -for-100) split. On January 30, 2023, we filed the Certificate of Amendment which set the authorized common stock to 500,000,000 and effected a 1 -for-35reverse stock split of our outstanding shares of common stock as of 12:01 a.m. Eastern Standard Time on February 1, 2023. Business Strategy and Pipeline Revelation is developing a pipeline of potential high -valueproducts based on Gemini.Gemini is Revelation’s proprietary formulation of phosphorylated hexaacyl disaccharide (“PHAD ®”) an established Toll -likereceptor 4 (TLR